NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb

Core Insights - NeoPhore Limited has secured additional funding from Bristol Myers Squibb to advance its research on the DNA mismatch repair (MMR) pathway in cancer and to progress its lead program towards candidate selection by 2025 [1][2]. Company Overview - NeoPhore is focused on developing small molecule drugs that target novel proteins within the MMR pathway, aiming to create next-generation immuno-oncology therapeutics to enhance clinical outcomes for cancer patients [2][3]. - The company was established as a spin-out from the University of Turin and PhoreMost Ltd, supported by the CRT Pioneer Fund [3]. Investment Details - The Series B extension round was oversubscribed, indicating strong investor interest and confidence in NeoPhore's approach [1][2]. - The funding will facilitate the completion of necessary pre-clinical studies for NeoPhore's lead PMS2 program [2]. Strategic Importance - The collaboration with Bristol Myers Squibb, a leader in the immuno-oncology field, is expected to bolster NeoPhore's position and accelerate its research efforts [2][4]. - NeoPhore's MMR inhibitors are designed to induce neoantigen expression, which enhances the immunogenicity of solid tumors, making them more responsive to immunotherapy [2].